Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose

Journal of Urology

Volumn 155, Issue 3, 1996, Pages 994-998

  Effert, Peter J ^a   Bares, Roland ^a   Handt, Stefan ^a   Wolff, Johannes M ^a   Büll, Udalrich ^a   Jakse, Gerhard ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Deoxyglucose; Fluorine radioisotopes; Prostatic neoplasms; Tomography, emission computed

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

ANTIMETABOLITES; DEOXYGLUCOSE; FLUORINE RADIOISOTOPES; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030061905     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(01)66366-3     Document Type: Article

References (20)

1. Jensen, O. M., Esteve, J., Moller, H. and Renard, H.: Cancer in the European Community and its member states. Eur. J. Cancer, 26: 1167, 1990.
2. Cancer Facts & Figures-1992. Atlanta: American Cancer Society, 1992.
3. Donohue, R. E., Mani, J. H., Whitesel, J. A., Mohr, S., Scanavino, D., Augspurger, R. R., Biber, R. J., Fauver, H. E., Wettlaufer, J. N., Pfister, R. R. and Williams, G.: Stage D1 adenocarcinoma of the prostate. Urology, 23: 118, 1984.
4. Stamey, T. A., McNeal, J. E., Freiha, F. S. and Redwine, E.: Morphometric and clinical studies on 68 consecutive radical prostatectomies. J. Urol., 139: 1235, 1988.
5. Rifkin, M. D., Zerhouni, E. A., Gatsonis, C. A., Quint, L. E., Paushter, D. M., Epstein, J. I., Hamper, U., Walsh, P. C. and McNeal, B. J.: Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: results of a multi-institutional cooperative trial. New Engl. J. Med., 323: 621, 1990.
6. Warburg, O.: The metabolism of tumors. London: Constable, 1930.
7. Tyler, J. L., Diksic, M., Villemure, J. G., Evans, A. C., Meyer, E., Yamamoto, Y. L. and Feindel, W.: Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J. Nucl. Med., 28: 1123, 1987.
8. Di Chiro, G., Hatazawa, J., Katz, D. A., Rizzoli, H. V. and De Michele, D. J.: Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and possibility of recurrence: a PET study. Radiology, 164: 521, 1987.
9. Di Chiro, G., Oldfield, E., Wright, D. C., De Michele, D., Katz, D. A., Patronas, N. J., Doppman, J. L., Larson, S. M., Ito, M. and Kufta, C. V.: Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR, 150: 189, 1988.
10. Valk, P. E., Budinger, T. F., Levin, V. A., Silver, P., Gutin, P. H. and Doyle, W. K.: PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J. Neurosurg., 69: 830, 1988.
11. Strauss, L. G. and Conti, P. S.: The applications of PET in clinical oncology. J. Nucl. Med., 32: 623, 1991.
12. Haberkorn, U., Strauss, L. G., Dimitrakopoulou, A., Seiffert, E., Oberdorfer, F., Ziegler, S., Reisser, C., Doll, J., Helus, F. and van Kaick, G.: Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J. Nucl. Med., 34: 12, 1993.
13. Bares, R., Effert, P., Handt, St., Hambuechen, U., Buell, U., Jakse, G. and Mittermayer, Ch.: Positron-emission-tomography (PET) with fluorine-18 labeled deoxyglucose (FDG) in prostatic cancer (PC): first results. J. Nucl. Med., 34: 217P, abstract 1021, 1993.
14. Shepp, L. A. and Vardi, Y.: Maximum likelihood reconstruction for emission tomography. IEEE Trans. Med. Imaging, 2: 113, 1982.
15. Inaba, T.: Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography. J. Urol., 148: 1457, 1992.
16. Watanabe, A., Tanaka, R., Takeda, N. and Washiyama, K.: DNA synthesis, blood flow, and glucose utilization in experimental rat brain tumors. J. Neurosurg., 70: 86, 1989.
17. Minn, H., Joensuu, H., Ahonen, A. and Klemi, P.: Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer, 61: 1776, 1988.
18. Bares, R., Klever, P., Hauptmann, S., Hellwig, D., Fass, J., Cremerius, U., Schumpelick, V., Mittermayer, C. and Büll, U.: F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology, 192: 79, 1994.
19. 18F-FDG PET in the evaluation of colorectal carcinoma. Eur. J. Nucl. Med., 16: 410, abstract 80, 1990.
20. Strauss, L. G., Tilgen, W., Dimitrakopoulou, A., Haberkorn, U., Knopp, M., Helus, F. and Maier-Borst, W.: PET studies with F-18-deoxyglucose (FDG) in patients with metastatic melanoma prior to and after therapy. J. Nucl. Med., abstract 403, 31: 804, 1990.